Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine

AAPS Journal

Volumn 11, Issue 2, 2009, Pages 353-363

  Bolger, Michael B ^a,b   Lukacova, Viera ^a   Woltosz, Walter S ^a  

^a Simulations Plus Inc   (United States)

^b NONE   (United States)

Author keywords

Expression; Intestine; Saturation; Simulation; Transporter

Indexed keywords

AMINO ACID TRANSPORTER; GABAPENTIN; GLYCOPROTEIN P; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1A2; ORGANIC CATION TRANSPORTER 1; PEPTIDE TRANSPORTER 1; TALINOLOL; UNCLASSIFIED DRUG; VALACICLOVIR;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; COMPUTER PREDICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; HUMAN; INTESTINE ABSORPTION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REPRODUCIBILITY; SIMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ACYCLOVIR; ADRENERGIC BETA-ANTAGONISTS; AMINES; ANIMALS; ANTIVIRAL AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CARRIER PROTEINS; COMPUTER SIMULATION; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; INTESTINES; NONLINEAR DYNAMICS; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PERMEABILITY; PROPANOLAMINES; RATS; SOLUBILITY; VALINE;

EID: 68249144520     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-009-9111-6     Document Type: Article

References (62)

1. Custodio JM, Wu CY, Benet LZ. Predicting drug disposition, absorption, elimination, transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008;60(6):717-33.
2. Nakamura T, Yamamori M, Sakaeda T. Pharmacogenetics of intestinal absorption. Curr Drug Deliv. 2008;5(3):153-69.
3. Steffansen B, Nielsen CU, Brodin B, Eriksson AH, Andersen R, Frokjaer S. Intestinal solute carriers: An overview of trends and strategies for improving oral drug absorption. Eur J Pharm Sci. 2004;21(1):3-16.
4. Sai Y, Tsuji A. Transporter-mediated drug delivery: Recent progress and experimental approaches. Drug Discov Today 2004;9(16):712-20.
5. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol Rev. 2003;55(3):425-61.
6. Tsuji A. Transporter-mediated drug interactions. Drug Metab Pharmacokinet. 2002;17(4):253-74.
7. Sadee W, Drubbisch V, Amidon GL. Biology of membrane transport proteins. Pharm Res. 1995;12(12):1823-37.
8. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11-23.
9. Ito K, Suzuki H, Horie T, Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm Res. 2005;22(10):1559-77.
10. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112(1):71-105.
11. Liu L, Cui Y, Chung AY, Shitara Y, Sugiyama Y, Keppler D, et al. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/ MRP2 in rat and human livers. J Pharmacol Exp Ther. 2006;318(1):395-402.
12. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci. 2006;27(5):425-46.
13. US FDA. Draft guidance for industry: Drug interaction studies - study design, data analysis, and implications for dosing and labeling, U.S.D.o.H.a.H. services, editor; 2006. Rockville: Center for Drug Evaluation and Research.
14. Yu LX, Amidon GL. Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm. 1998;45(2):199-203.
15. Tubic M, Wagner D, Spahn-Langguth H, Bolger MB, Langguth P. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm Res. 2006;23(8):1712-20.
16. Bolger MB, Haworth IS, Yeung AK, Ann D, von Grafenstein H, Hamm-Alvarez S, et al. Structure, function, and molecular modeling approaches to the study of the intestinal dipeptide transporter PepT1. J Pharm Sci. 1998;87(11):1286-91.
17. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev. 2001;50(Suppl 1):S41-67.
18. Gonzalez-Alvarez I, Fernandez-Teruel C, Casabo-Alos VG, Garrigues TM, Polli JE, Ruiz-Garcia A, et al. In situ kinetic modelling of intestinal efflux in rats: Functional characterization of segmental differences and correlation with in vitro results. Biopharm Drug Dispos. 2007;28(5):229-39.
19. Kwon H, Lionberger RA, Yu LX. Impact of P-glycoprotein-mediated intestinal efflux kinetics on oral bioavailability of P-glycoprotein substrates. Mol Pharm. 2004;1(6):455-65.
20. Pang KS. Modeling of intestinal drug absorption: Roles of transporters and metabolic enzymes. Drug Metab Dispos. 2003;31(12):1507-19.
21. Reigner BG, Couet W, Guedes JP, Fourtillan JB, Tozer TN. Saturable rate of cefatrizine absorption after oral administration to humans. J Pharmacokinet Biopharm. 1990;18(1):17-34.
22. Sinko PJ, Amidon GL. Characterization of the oral absorption of beta-lactam antibiotics. I. Cephalosporins: Determination of intrinsic membrane absorption parameters in the rat intestine in situ. Pharm Res. 1988;5(10):645-50.
23. Englund G, Rorsman F, Ronnblom A, Karlbom U, Lazorova L, Grasjo J, et al. Regional levels of drug transporters along the human intestinal tract: Co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur J Pharm Sci. 2006;29(3-4):269-77.
24. Herrera-Ruiz D, Wang Q, Gudmundsson OS, Cook TJ, Smith RL, Faria TN, et al. Spatial expression patterns of peptide transporters in the human and rat gastrointestinal tracts, Caco-2 in vitro cell culture model, and multiple human tissues. AAPS PharmSci. 2001;3(1):E9.
25. Meier Y, Eloranta JJ, Darimont J, Ismair MG, Hiller C, Fried M, et al. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos. 2007;35(4):590-4.
26. Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res. 2003;20(10):1595-9.
27. Shirasaka Y, Li Y, Shibue Y, Kuraoka E, Spahn-Langguth H, Kato Y, et al. Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by P-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm Res 2009;26:560-7.
28. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004;447(5):653-65.
29. Dave MH, Schulz N, Zecevic M, Wagner CA, Verrey F. Expression of heteromeric amino acid transporters along the murine intestine. J Physiol. 2004;558(Pt 2):597-610.
30. Sinko PJ, Balimane PV. Carrier-mediated intestinal absorption of valacyclovir, the l-valyl ester prodrug of acyclovir: 1. Interactions with peptides, organic anions and organic cations in rats. Biopharm Drug Dispos. 1998;19:209-17.
31. Urban TJ, Brown C, Castro RA, Shah N, Mercer R, Huang Y, et al. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008;83(3):416-21.
32. Uchino H, Kanai Y, Kim do K, Wempe MF, Chairoungdua A, Morimoto E, et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): Insights into the mechanisms of substrate recognition. Mol Pharmacol. 2002;61(4):729-37.
33. Doppenschmitt S, Spahn-Langguth H, Regardh CG, Langguth P. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J Pharm Sci. 1999;88(10):1067-72.
34. Han H, de Vrueh RL, Rhie JK, Covitz KM, Smith PL, Lee CP, et al. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res. 1998;15(8):1154-9.
35. Landowski CP, Sun D, Foster DR, Menon SS, Barnett JL, Welage LS, et al. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther. 2003;306(2):778-86.
36. Balimane P, Sinko P. Effect of ionization on the variable uptake of valacyclovir via the human intestinal peptide transporter (hPepT1) in CHO cells. Biopharm Drug Dispos. 2000;21(5):165-74.
37. Han HK, Oh DM, Amidon GL. Cellular uptake mechanism of amino acid ester prodrugs in Caco-2/hPEPT1 cells overexpressing a human peptide transporter. Pharm Res. 1998;15(9):1382-6.
38. Adson A, Burton PS, Raub TJ, Barsuhn CL, Audus KL, Ho NF. Passive diffusion of weak organic electrolytes across Caco-2 cell monolayers: uncoupling the contributions of hydrodynamic, transcellular, and paracellular barriers. J Pharm Sci. 1995;84(10):1197-204.
39. Weller S, Blum MR, Doucette M, Burnette T, Cederberg DM, de Miranda P, et al. Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single- and multiple-dose administration to normal volunteers. Clin Pharmacol Ther. 1993;54(6):595-605.
40. Soul-Lawton J, Seaber E, On N, Wootton R, Rolan P, Posner J. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans. Antimicrob Agents Chemother. 1995;39(12):2759-64.
41. MacDougall C, Guglielmo BJ. Pharmacokinetics of valaciclovir. J Antimicrob Chemother. 2004;53(6):899-901.
42. del Amo EM, Urtti A, Yliperttula M. Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2. Eur J Pharm Sci. 2008;35(3):161-74.
43. Madan J, Chawla G, Arora V, Malik R, Bansal AK. Unbiased membrane permeability parameters for gabapentin using boundary layer approach. AAPS J. 2005;7(1):E224-30.
44. Meier C, Ristic Z, Klauser S, Verrey F. Activation of system L heterodimeric amino acid exchangers by intracellular substrates. EMBO J. 2002;21(4):580-9.
45. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernas H, Hussain AS, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm. 2004;1(1):85-96.
46. Berezhkovskiy LM. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci. 2004;93(6):1628-40.
47. Vollmer KO, von Hodenberg A, Kolle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung 1986;36(5):830-9.
48. Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 2000;40(2-3):123-7.
49. Gidal BE, DeCerce J, Bockbrader HN, Gonzalez J, Kruger S, Pitterle ME, et al. Gabapentin bioavailability: Effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 1998;31(2):91-9.
50. Gordi T, Hou E, Kasichayanula S, Berner B. Pharmacokinetics of gabapentin after a single day and at steady state following the administration of gastric-retentive-extended-release and immediate-release tablets: A randomized, open-label, multiple-dose, three-way crossover, exploratory study in healthy subjects. Clin Ther. 2008;30(5):909-16.
51. Seelig A. A general pattern for substrate recognition by P-glycoprotein. Eur J Biochem. 1998;251(1-2):252-61.
52. de Mey C, Schroeter V, Butzer R, Jahn P, Weisser K, Wetterich U, et al. Dose-effect and kinetic-dynamic relationships of the beta-adrenoceptor blocking properties of various doses of talinolol in healthy humans. J Cardiovasc Pharmacol. 1995;26(6):879-8.
53. Tang H, Pak Y, Mayersohn M. P-glycoprotein (P-gp) mRNA and protein expression pattern along the small intestine of the Yucatan micropig. AAPS Annual Meeting. 2002. Toronto, Canada.
54. Tang H, Pak Y, Mayersohn M. Protein expression pattern of P-glycoprotein along the gastrointestinal tract of the Yucatan micropig. J Biochem Mol Toxicol. 2004;18(1):18-22.
55. Naruhashi K, Sai Y, Tamai I, Suzuki N, Tsuji A. PepT1 mRNA expression is induced by starvation and its level correlates with absorptive transport of cefadroxil longitudinally in the rat intestine. Pharm Res. 2002;19(10):1417-23.
56. Rossier G, Meier C, Bauch C, Summa V, Sordat B, Verrey F, et al. LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine. J Biol Chem. 1999;274(49):34948-54.
57. Troutman MD, Thakker DR. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: Asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003;20(8):1200-9.
58. Korjamo T, Kemilainen H, Heikkinen AT, Monkkonen J. Decrease in intracellular concentration causes the shift in K m value of efflux pump substrates. Drug Metab Dispos. 2007;35(9):1574-9.
59. Gramatte T, Oertel R, Terhaag B, Kirch W. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin Pharmacol Ther. 1996;59(5):541-9.
60. Trausch B, Oertel R, Richter K, Gramatte T. The protein binding of talinolol. Pharmazie 1995;50(1):72.
61. Trausch B, Oertel R, Richter K, Gramatte T. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos. 1995;16(5):403-14.
62. Kim JS, Mitchell S, Kijek P, Tsume Y, Hilfinger J, Amidon GL. The suitability of an in situ perfusion model for permeability determinations: Utility for BCS class I biowaiver requests. Mol Pharm. 2006;3(6):686-94.